ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 484 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2025-03-28
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was -6.76K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 0.00 shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-06-30 was 2.75K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-03-31 was 4.49K shares.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 484.00 shares, a 59.67% decline from fiscal 2023.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.20K shares, a 20.00% increase from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -6.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -6.76K shares derived: sum of 2 quarters · filed 2025-03-28 | -4.01K shares derived: sum of 3 quarters · filed 2025-03-28 | 484.00 shares 10-K · filed 2025-03-28 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 2.75K shares derived: sum of 2 quarters · filed 2024-11-14 | 7.25K shares 10-Q · filed 2024-11-14 | -8.03K shares derived: sum of 4 quarters · filed 2025-03-28 | |
| 2024-06-30 | 2.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 7.25K shares 10-Q · filed 2024-08-12 | -8.03K shares derived: sum of 3 quarters · filed 2025-03-28 | ||
| 2024-03-31 | 4.49K shares 10-Q · filed 2024-05-15 | -10.78K shares derived: sum of 2 quarters · filed 2025-03-28 | |||
| 2023-12-31 | -15.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 1.20K shares 10-K · filed 2025-03-28 | 18.00K shares 10-K · filed 2024-03-26 | ||
| 2023-09-30 | 16.48K shares 10-Q · filed 2023-11-13 | ||||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-26 | 1.00K shares 10-K · filed 2024-03-26 | ||
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.00K shares 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 1.00K shares 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |